ESC Premium Access

Current state of knowledge on the mechanism of action of bempedoic acid and its potential for LDL-C lowering and CV risk reduction.

Congress Presentation

About the speaker

Professor Stephen Nicholls

Monash University, Melbourne (Australia)
51 presentations

3 more presentations in this session

PCSK9 inhibitors post Fourier: who should be treated and when?

Speaker: Professor S. Nissen (Cleveland, US)


siRNA therapy: the dawn of a new agent in cholesterol lowering?

Speaker: Doctor L. Cho (Cleveland, US)


Is Lp(a) a risk factor for cardiovascular disease and is it worth treating?

Speaker: Professor E. Stroes (Amsterdam, NL)


Access the full session

Cardiovascular risk reduction and dyslipidaemia management: current state and future therapies

Speakers: Professor S. Nicholls, Professor S. Nissen, Doctor L. Cho, Professor E. Stroes

About the event


ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb